## Prostaglandin E1

**Indication**: Other specified congenital anomaly of great arteries including arterial duct

**INN**: Alprostadil

**Medicine type**: Chemical agent

**List type**: Complementary (EML) (EMLc)

**Formulations**: Parenteral > General injections > IV: 0.5 mg per mL in alcohol (EMLc)

**EML status history**: First added in 2009 (TRS 958) Changed in 2021 (TRS 1035)

**Sex**: All

**Age**: Newborn (< 1 month)

**Therapeutic alternatives**: Prostaglandin E2 (ATC codes: G02AD02) Parenteral > General injections > IV: 1 mg per mL

**Patent information**: Patents have expired in most jurisdictions Read more about patents.

**Wikipedia**: Prostaglandin E1

**DrugBank**: Prostaglandin e (Alprostadil)

### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended to retain the square box for prostaglandin E, but assign it to prostaglandin E1, and specify prostaglandin E2 as an alternative on the EMLc for this indication.